Perceptive Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-1,272,694
Closed -$137M 111
2023
Q1
$137M Buy
1,272,694
+60,000
+5% +$6.91M 4.03% 6
2022
Q4
$133M Sell
1,212,694
-255,818
-17% -$16.6M 3.75% 5
2022
Q3
$86.7M Sell
1,468,512
-213,730
-13% -$9.78M 2.52% 13
2022
Q2
$47.5M Sell
1,682,242
-758,340
-31% -$22M 1.49% 15
2022
Q1
$92.2M Sell
2,440,582
-732,203
-23% -$28.9M 1.85% 13
2021
Q4
$125M Sell
3,172,785
-141,247
-4% -$4.42M 1.93% 12
2021
Q3
$78.6M Hold
3,314,032
1.14% 24
2021
Q2
$81.4M Hold
3,314,032
1.06% 26
2021
Q1
$55.4M Buy
+3,314,032
New +$68.4M 0.7% 40

Other funds holding RXDX

Perceptive Advisors's RXDX Position: Q2 2023 in Review

Perceptive Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 1,272,694 shares — an estimated $137M sold.

Perceptive Advisors first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $137M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

  • Perceptive Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Perceptive Advisors sold 1,272,694 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $137M.
  • Perceptive Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Perceptive Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $137M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.